Tirzepatide Inj recall
FDA recall D-0394-2026 · initiated Feb 26, 2026
New Life Pharma LLC recalled Tirzepatide Inj in Feb 2026 — an FDA Class II recall (D-0394-2026) because Lack of Assurance of Sterility.
May cause temporary or medically reversible harm; low probability of serious harm.
Why it was recalled
Lack of Assurance of Sterility
Sterility could not be assured
The maker could not guarantee the product was sterile. That matters most for injections and eye products, where a contaminated dose reaches past the body's defences.
This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.
Is your product affected? Check the lot number
A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.
Quantity recalled: 23 vials
Details
- Product
- Tirzepatide Inj, 10mg, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-002-03.
- Recalling company
- New Life Pharma LLC
- Classification
- Class II
- Status
- Ongoing
- Type
- Voluntary: Firm initiated
- Distribution
- OH
- Initiated
- Feb 26, 2026
- FDA report date
- Mar 11, 2026
Frequently asked
- Was Tirzepatide Inj recalled?
- New Life Pharma LLC recalled Tirzepatide Inj in Feb 2026 — an FDA Class II recall (D-0394-2026) because Lack of Assurance of Sterility. May cause temporary or medically reversible harm; low probability of serious harm.
- Why was Tirzepatide Inj recalled?
- Per the FDA enforcement record, the reason for recall D-0394-2026 was: Lack of Assurance of Sterility
- Is a recalled Tirzepatide Inj dangerous to take?
- An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
- Which lots of Tirzepatide Inj are affected?
- Distributed: OH. The recall covers these lots — Lot 240709, exp 7/31/2026. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0394-2026.